Physician profile
Ruby De La Torre
NPI 1851764146
$16,575.87
in general payments reported to CMS, 2019-2025
33 companies · $4,319 in 2025
The $4,319 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $2,327 · 2023: $4,200 · 2024: $5,122 · 2025: $4,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,783.48 |
| Education | $858.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,025.97 | 2022-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $2,008.34 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,252.40 | 2021-2025 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $1,224.68 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,179.41 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Pfizer INC. | $1,154.86 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,102.64 | 2022-2024 | Vtama |
| Incyte Corporation | $1,073.26 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $954.37 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $871.99 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $400.16 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $375.39 | 2023-2025 | Zoryve |
| Ucb, INC. | $362.39 | 2022-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $335.65 | 2021-2025 | |
| Organon LLC | $327.17 | 2024-2025 | Vtama, Hadlima |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $321.06 | 2022-2024 | |
| Almirall LLC | $315.62 | 2021-2025 | Klisyri, Seysara |
| Amgen INC. | $208.21 | 2021-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $178.04 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $162.77 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.66 | 2022-2025 | Jublia, Cabtreo, Siliq |
| Galderma Laboratories, L.P. | $124.78 | 2021-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.42 | 2023-2024 | Spevigo, Cyltezo |
| Janssen Scientific Affairs, LLC | $89.71 | 2022 | |
| Biofrontera INC. | $69.46 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Epi Health, LLC | $61.95 | 2022 | |
| Mayne Pharma Commercial LLC | $51.06 | 2025 | |
| Sandoz INC. | $33.65 | 2023-2024 | Hyrimoz |
| Cipher Pharmaceuticals US LLC | $18.91 | 2025 | Spinosad, Natroba |
| Kyowa Kirin, INC. | $17.21 | 2023 | Poteligeo |
| Organogenesis INC. | $17.17 | 2025 | Puraply Wound Matrix |
| Medtronic, INC. | $15.31 | 2022 | |
| Merz North America, INC. | $13.20 | 2023 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby De La Torre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.